Latest FluMist Stories

Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines

2013-05-24 04:20:39

BEIJING, May 24, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging...

iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza

2013-05-22 08:27:43

NEWARK, Del., May 22, 2013 /PRNewswire/ -- PRNewswire - iBio, Inc. (NYSE MKT: IBIO) today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch(TM) platform. This validation milestone was achieved in 21 days as measured from initial antigen sequence information to purification of recombinant protein. (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO ) The iBioLaunch...

Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak

2013-05-20 00:21:38

OAKLAND, Calif., May 20, 2013 /PRNewswire/ -- Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics. Whole-cell pertussis vaccines, also called DTwP, were available from the 1940s to 1990s, but were associated with safety concerns that ultimately led to the development of acellular pertussis vaccines, which are also called...

Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results

2013-05-17 04:20:46

BEIJING, May 17, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2013, before market on Tuesday, May 28, 2013. The Company will host a conference call on Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate...

A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing

2013-05-17 00:20:09

The vaccine based on Cytos' Virus-Like Particle technology may open the door to accelerated production of influenza vaccines in SingaporeSingapore and Schlieren (Zurich), Switzerland, May 17, 2013 - (ACN Newswire) - Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos'...

Sinovac Appoints Ernst & Young Hua Ming Llp China as External Auditor

2013-05-15 08:29:21

BEIJING, May 15, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst & Young LLP Canada. On May 14, 2013, Ernst & Young LLP Canada notified the Company that it would not stand for re-election as the Company's registered independent public accounting firm....

Sinovac Presents at the UBS Global Healthcare Conference in May 2013

2013-05-14 08:31:46

BEIJING, May 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that management is scheduled to present at the UBS Global Healthcare Conference in New York City. The Sinovac management team inclusive of Nan Wang, Vice President, and Helen Yang, Director, Investor Relations and International Business Development, will present at 10:00 am ET on Monday, May 20, 2013. About Sinovac Sinovac...

NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative

2013-05-13 12:28:34

NES ZIONA, Israel, May 13, 2013 /PRNewswire/ -- NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia. This collaboration is a part of NanoPass's long-term commitment to improve Global Health by providing access to its vaccine delivery devices....

Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results

2013-05-10 16:25:03

BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013. Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per...

Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China

2013-05-08 08:29:35

-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9- QUEBEC CITY, May 8, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is...